Disturbances in beta-cell function in impaired fasting glycemia

Area of Science:

• Endocrinology
• Metabolic Disorders
• Diabetes Research

Background:

• Glucose intolerance, including impaired fasting glycemia (IFG) and type 2 diabetes, represents a spectrum of metabolic dysfunction.
• Understanding the progression of beta-cell dysfunction and insulin resistance is crucial for effective diabetes management.

Purpose of the Study:

• To assess beta-cell function and insulin sensitivity in individuals with normal fasting glycemia (NFG), IFG, and type 2 diabetes.
• To investigate the relationship between glucose tolerance status and the progression of beta-cell dysfunction and insulin resistance.

Main Methods:

• Cross-sectional study involving hyperglycemic clamps to measure first- and second-phase insulin release.
• Assessment of insulin sensitivity index (ISI) in relation to fat-free mass.
• Categorization of participants into NFG, IFG, and type 2 diabetes groups based on fasting plasma glucose (FPG) levels.

Main Results:

• First-phase insulin release was significantly lower in IFG and type 2 diabetes compared to NFG.
• Second-phase insulin secretion also showed a decline in IFG and type 2 diabetes.
• Insulin sensitivity index (ISI) was reduced in IFG and type 2 diabetes subjects compared to NFG, with more pronounced insulin resistance observed in later stages of glucose intolerance.

Conclusions:

• Early stages of glucose intolerance are characterized by impaired beta-cell function, specifically reduced insulin secretion.
• Insulin resistance becomes a more prominent feature as glucose intolerance progresses to later stages.
• These findings highlight a stepwise deterioration in both beta-cell function and insulin sensitivity along the continuum of glucose intolerance.